Neurofibromatosis type II

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024
AXIN1, Research, Partnership, Clostridioides difficile infection, Development, IND, DeepMind, NVIDIA, Biomarker, Drug discovery, Tempus, Pharmacokinetics, Map, ADME, Machine learning, Software, Appetite, Roche, APC, Infection, Neurofibromatosis type II, CCM, Transcriptome, Safety, Johnson & Johnson, Neuroscience, RNA, Artificial intelligence, FAP, Data science, Therapy, Translation, Chemistry, RBM39, Biology, Clinical trial, LILAC, NF2, University of Oxford, Recurrence, Computational biology, Hemangioma, Administration, Patient, Strategy, Trial of the century, Pharmaceutical industry

L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Key Points: 
  • L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.
  • Revenue: Total revenue was $13.8 million for the first quarter of 2024, compared to $12.1 million for the first quarter of 2023.
  • Research and Development Expenses: Research and development expenses were $67.6 million for the first quarter of 2024, compared to $46.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $91.4 million for the first quarter of 2024, compared to a net loss of $65.3 million for the first quarter of 2023.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
FAP, Senior, Research, FPI, Chemistry, Neuroscience, AXIN1, Part, Death, LLM, Software as a service, Hemangioma, Genetics, Cancer, Software, Letter, Business operations, Data, Matchmaker, APC, Machine learning, Real space, Biology, Development, Partnership, Therapy, Enamine, CCM, Myrexis, Library, Drug discovery, Safety, Biomarker, Clinical trial, IND, Clostridioides difficile infection, Roche, NF2, Biotechnology, Neurofibromatosis type II, Trial of the century, LILAC, Disease, Myriad Genetics, Administration, Pharmaceutical industry

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Key Points: 
  • SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
  • Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.

Vibe Bio Launches To Transform Drug Development For Patients With Rare Diseases

Retrieved on: 
Wednesday, June 22, 2022
Biotechnology, General Health, Pharmaceutical, Health, Doctor of Philosophy, Time, Therapy, Drug development, Degenerative disease, Myoclonus, CEO, Initialized Capital, Neurofibromatosis type II, VIBE, Biotechnology, Research, Lafora, Growth, Epilepsy, Disease, DAO, Ownership, National, NICU, Quality of life, Tayy, Naval Ravikant, Patient, Organization, Lafora disease, Nervous system, Pharmaceutical industry, Health insurance

By leveraging a decentralized autonomous organization (DAO), Vibe Bio builds a global community of patients, scientists, and partners around a shared mission to cure rare diseases.

Key Points: 
  • By leveraging a decentralized autonomous organization (DAO), Vibe Bio builds a global community of patients, scientists, and partners around a shared mission to cure rare diseases.
  • For the first time, Vibe Bio is giving patients with rare and overlooked diseases access to the funding and community support they need to develop cures and ownership over the results.
  • Vibe Bio has already partnered with two patient advocacy organizations to launch and fund independent biotechnology companies to pursue promising therapeutics for rare and often fatal diseases.
  • We work together to identify promising treatments for rare and overlooked diseases and fund their development through $VIBE cryptocurrency token sales.

Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Cancer, Cytoskeleton, Merlin, Mesothelioma, Health, Neurofibromatosis type II

The study is currently in dose escalation, to be followed by a dose expansion phase in which patients with NF2 mutant tumors will be enrolled after an optimal dose is determined.

Key Points: 
  • The study is currently in dose escalation, to be followed by a dose expansion phase in which patients with NF2 mutant tumors will be enrolled after an optimal dose is determined.
  • "To the best of our knowledge, we are the first company to test a small molecule in the clinic targeting this important pathway.
  • We are enrolling patients with a variety of signaling abnormalities during dose escalation and will allow NF2-mutated patients to backfill any previously cleared dose cohorts.
  • NF2 mutation can occur in many tumor types, including a high percentage of mesothelioma and meningioma.\n'